Cited 0 times in
Immunological Characteristics of Hyperprogressive Disease in Patients with Non-small Cell Lung Cancer Treated with Anti-PD-1/PD-L1 Abs
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김경환 | - |
dc.contributor.author | 신의철 | - |
dc.date.accessioned | 2021-05-26T16:43:18Z | - |
dc.date.available | 2021-05-26T16:43:18Z | - |
dc.date.issued | 2020-12 | - |
dc.identifier.issn | 1598-2629 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/182808 | - |
dc.description.abstract | Hyperprogressive disease (HPD) is a distinct pattern of progression characterized by acceleration of tumor growth after treatment with anti-PD-1/PD-L1 Abs. However, the immunological characteristics have not been fully elucidated in patients with HPD. We prospectively recruited patients with metastatic non-small cell lung cancer treated with anti-PD-1/PD-L1 Abs between April 2015 and April 2018, and collected peripheral blood before treatment and 7-days post-treatment. HPD was defined as ≥2-fold increase in both tumor growth kinetics and tumor growth rate between pre-treatment and post-treatment. Peripheral blood mononuclear cells were analyzed by multi-color flow cytometry to phenotype the immune cells. Of 115 patients, 19 (16.5%) developed HPD, 52 experienced durable clinical benefit (DCB; partial response or stable disease ≥6 months), and 44 experienced non-hyperprogressive progression (NHPD). Patients with HPD had significantly lower progression-free survival (p<0.001) and overall survival (p<0.001). When peripheral blood immune cells were examined, the pre-treatment frequency of CD39+ cells among CD8+ T cells was significantly higher in patients with HPD compared to those with NHPD, although it showed borderline significance to predict HPD. Other parameters regarding regulatory T cells or myeloid derived suppressor cells did not significantly differ among patient groups. Our findings suggest high pre-treatment frequency of CD39+CD8+ T cells might be a characteristic of HPD. Further investigations in a larger cohort are needed to confirm our results and better delineate the immune landscape of HPD. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Korea Society for Immunology : Korean Society of Biological Response Modifiers | - |
dc.relation.isPartOf | IMMUNE NETWORK | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Immunological Characteristics of Hyperprogressive Disease in Patients with Non-small Cell Lung Cancer Treated with Anti-PD-1/PD-L1 Abs | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Radiation Oncology (방사선종양학교실) | - |
dc.contributor.googleauthor | Kyung Hwan Kim | - |
dc.contributor.googleauthor | Joon Young Hur | - |
dc.contributor.googleauthor | Jiae Koh | - |
dc.contributor.googleauthor | Jinhyun Cho | - |
dc.contributor.googleauthor | Bo Mi Ku | - |
dc.contributor.googleauthor | June Young Koh | - |
dc.contributor.googleauthor | Jong-Mu Sun | - |
dc.contributor.googleauthor | Se-Hoon Lee | - |
dc.contributor.googleauthor | Jin Seok Ahn | - |
dc.contributor.googleauthor | Keunchil Park | - |
dc.contributor.googleauthor | Myung-Ju Ahn | - |
dc.contributor.googleauthor | Eui-Cheol Shin | - |
dc.identifier.doi | 10.4110/in.2020.20.e48 | - |
dc.contributor.localId | A05226 | - |
dc.contributor.localId | A02137 | - |
dc.relation.journalcode | J01033 | - |
dc.identifier.eissn | 2092-6685 | - |
dc.identifier.pmid | 33425433 | - |
dc.subject.keyword | CD39 | - |
dc.subject.keyword | Hyperprogressive disease | - |
dc.subject.keyword | Lung cancer | - |
dc.subject.keyword | PD-1-PD-L1 blockade | - |
dc.subject.keyword | Peripheral blood human mononuclear cells | - |
dc.subject.keyword | T cell | - |
dc.contributor.alternativeName | Kim, Kyung Hwan | - |
dc.contributor.affiliatedAuthor | 김경환 | - |
dc.contributor.affiliatedAuthor | 신의철 | - |
dc.citation.volume | 20 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | e48 | - |
dc.identifier.bibliographicCitation | IMMUNE NETWORK, Vol.20(6) : e48, 2020-12 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.